CD4 and COVID-19: MILD COVID-19 patient exosomes are able to activate both autologous and heterologous CD4+ T helper cells and induce IL-2 secretion in vitro, suggesting that in vivo, they could enhance the immune responses elicited against SARS-CoV-2 antigens, thereby possibly contributing to a better outcome or more rapid resolution of the infection.